Involving Proteinase Patents (Class 435/23)
-
Publication number: 20130315876Abstract: The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage.Type: ApplicationFiled: January 7, 2013Publication date: November 28, 2013Inventor: UNIVERSITY OF CONNECTICUT
-
Publication number: 20130315955Abstract: The present invention relates to methods of improving the stability and maintaining the potency of recombinant hemagglutinin formulations, in particular, recombinant influenza hemagglutinin (rHA). In particular, Applicants have shown that the stability of rHA formulations may be significantly improved by mutating cysteine residues or by formulating with a reducing agent and sodium citrate.Type: ApplicationFiled: March 15, 2013Publication date: November 28, 2013Applicant: Protein Sciences CorporationInventors: Kathleen Holtz, Erin Matthews, David Rhodes, Indresh Srivastava
-
Patent number: 8592142Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.Type: GrantFiled: December 10, 2012Date of Patent: November 26, 2013Assignee: Momenta Pharmaceuticals, Inc.Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
-
Patent number: 8594947Abstract: The present invention relates to a crystal of ACE protein. The present invention further relates to methods, processes, ACE modulators, pharmaceutical compositions and uses of the ACE crystal and the structure co-ordinates thereof.Type: GrantFiled: February 26, 2010Date of Patent: November 26, 2013Assignees: University of Bath, University of Cape TownInventors: Ravi Acharya, Edward Sturrock
-
Publication number: 20130309671Abstract: Described herein is a time-gated, two-step FRET relay effective to provide temporal transference of a prompt FRET pathway, or provide spectro-temporal encoding analytical signals and other information. A FRET relay assembly includes a long lifetime FRET donor (for example, a lanthanide complex), a semiconductor quantum dot (QD) configured as an intermediate acceptor/donor in FRET, and a fluorescent dye configured as a terminal FRET acceptor, wherein the long lifetime FRET donor has an excited state lifetime of at least one microsecond and the QD and fluorescent dye each have excited state lifetimes of less than 100 nanoseconds.Type: ApplicationFiled: June 6, 2013Publication date: November 21, 2013Applicant: The Government of the United States of America, as represented by the Secretary of the NavyInventors: W. Russ Algar, Niko Hildebrandt, Alan L. Huston, Igor L. Medintz
-
Publication number: 20130309704Abstract: The purpose of the present invention is to improve the measurement accuracy in the measurement of the concentration of a physiologically active biological substance in a sample by a stirring turbidimetry, a light scattering method or an AL-bound beads method, wherein the purpose can be achieved by preventing the occurrence of aggregation or gelation that is caused by the stirring of a mixed solution and is not associated with the physiologically active substance.Type: ApplicationFiled: January 26, 2012Publication date: November 21, 2013Applicant: KOWA COMPANY, LTD.Inventors: Katsuya Inada, Shigeatsu Endo, Taisuke Hirono, Takaharu Asano
-
Patent number: 8584892Abstract: A packet of an enzyme and/or enzyme producing bacteria is contained within the core of a roll of toilet tissue or similar paper product wound on a core. The packet has a cover that dissolves or disintegrates on contact with water and disperses its contents into the aqueous waste stream. The packet may contain a mixture of bacterial cultures that produce enzymes to attack the greasy or fatty components of the waste stream. An additional article such as a sample of a liquid or creme personal care product may also be contained within the tissue paper core.Type: GrantFiled: January 19, 2010Date of Patent: November 19, 2013Inventor: Joseph R. Lira
-
Patent number: 8586526Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.Type: GrantFiled: May 17, 2011Date of Patent: November 19, 2013Assignee: Sangamo BioSciences, Inc.Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
-
Patent number: 8586325Abstract: Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.Type: GrantFiled: May 10, 2013Date of Patent: November 19, 2013Assignee: Biotium, Inc.Inventors: Fei Mao, Hui Cen
-
Patent number: 8585972Abstract: One object of the present invention is to provide a biosensor and a production method therefor, by which hydrogel that enables immobilization of a physiologically active substance can be conveniently produced using safe raw materials. The present invention provides a biosensor which comprises a substrate having a metal layer on its surface, wherein a hydrophilic polymer having a reactive functional group capable of reacting with a hydroxyl group or an amino group of a physiologically active substance is bound to the metal layer directly or indirectly via an intermediate layer.Type: GrantFiled: May 12, 2010Date of Patent: November 19, 2013Assignee: FUJIFILM CorporationInventors: Taisei Nishimi, Toshihide Ezoe, Toshiaki Kubo, Hidetoshi Tomita
-
Publication number: 20130302328Abstract: This disclosure provides ten (10) specific peptides, and particular peptide characteristics, from the cell membrane-bound Her2 protein and a diagnostic assay useful for determining the presence and amount of full length and truncated versions of the full-length Her2 protein in cells derived from formalin fixed paraffin embedded tissue.Type: ApplicationFiled: December 8, 2011Publication date: November 14, 2013Applicant: Expression Pathology, Inc.Inventor: David Krizman
-
Publication number: 20130302334Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 15, 2013Publication date: November 14, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 8580534Abstract: A method for comparative proteomics using a peptidase under enzymatic conditions that permits the optimal incorporation of two oxygen atoms into a digested peptide. The method employs a peptidase to incorporate two 18O atoms into a peptide set derived from a population of proteins at a conditioned state, which is compared to a second peptide set incorporated with a single 16O atom derived from a population of proteins at a second conditioned state. Upon combining the two peptide sets, the populations of proteins are analyzed for qualitative and quantitative differences based on the content of 18O atoms and 16O atoms in the digested peptides using mass spectrometry instrumentation. The method is advantageous to improve the efficiency and timeframe of peptidase catalyzed 18O labeling reactions which increased the accuracy and reliability of quantitative proteomic experiments.Type: GrantFiled: July 2, 2007Date of Patent: November 12, 2013Assignee: The University of North DakotaInventor: Masaru Miyagi
-
Patent number: 8580533Abstract: The present invention provides methods for enhancing chemical reactions of molecules, e.g., biomolecules, with destructible surfactants. The chemical reactions may involve and/or be associate with analysis, e.g., solubilizing, separating, purifying and/or characterizing the molecules. In one aspect, the anionic surfactants of the present invention may be selectively broken up at relatively low pH. The resulting breakdown products of the surfactants may be removed from the molecule/sample with relative ease. The invention has applicability in a variety of analytical techniques.Type: GrantFiled: May 30, 2003Date of Patent: November 12, 2013Assignee: Waters Technologies CorporationInventors: Edouard S. P. Bouvier, Bruce J. Compton, John C. Gebler, Martin Gilar, Ying-Qing Yu, Peter Jeng-Jong Lee, Elizabeth K. Brown
-
Publication number: 20130295590Abstract: The present invention provides for a proteomic approach to predicting, diagnosing and staging invasive bladder cancer, and for predicting patient survival and therapeutic efficacy. More specifically, the target being analyzed for reduced expression is FOXA1, and optionally including analysis of increased FOXA2 expression.Type: ApplicationFiled: November 8, 2011Publication date: November 7, 2013Applicants: The Regents of the University of Colorado, A body Corporate, VANDERBILT UNIVERSITYInventors: David Degraff, Robert Matusik, Peter Clark, Dan Theodorescu
-
Publication number: 20130295597Abstract: A sample preparation and analysis system. The system 10 includes a sample preparation system 12 and a sample analysis system 14. The sample preparation system 12 prepares samples in accordance with an assay that is selected from a database containing a plurality of unique assays. The sample analysis system 14 includes an analyzer 110 that is dynamically reconfigurable based on the selected assay so as to analyze the prepared sample in accordance with that selected assay. A data communication link 115a communicates data from the sample preparation system 12 to the sample analysis system 14 to reconfigure the analyzer 110 in accordance with the selected assay.Type: ApplicationFiled: October 28, 2011Publication date: November 7, 2013Applicant: Thermo Fisher Scientific OyInventors: Robert DeWitte, Juhani Siidorov, Vesa Nuotio, Raimo Salminen, Jarmo Vehkomaki, Jukka Saukkonen, Bill Ostman, Joseph M. Senteno, John Edward Brann, III, Joseph L. Herman, Jeffrey A. Zonderman, Terry N. Olney
-
Publication number: 20130295596Abstract: The present invention relates to a process for the prediction of cell culture performance data of sample cells, a process for the isolation of said cells and a device for the prediction of cell culture performance data of sample cells.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicant: LONZA BIOLOGICS PLCInventors: Dietmar Lang, Elaine B. Martin, Gary A. Montague, Christopher J. O'Malley, Tracy S. Root, Carol M. Trim, Jane F. Povey, Christopher M. Smales, Andrew J. Racher
-
Publication number: 20130295579Abstract: A method for preparing induced pluripotent stem (iPS) cells, which comprises steps as follows: step 1, introducing one or more stem cell pluripotency factors into somatic cells; step 2, culturing the somatic cells, into which the stem cell pluripotency factor has been introduced in the Step 1, by using medium supplemented with lithium salt; and step 3, identifying and characterizing the induced pluripotent stem cells. Furthermore, there provided a medium for preparing induced pluripotent stem cells, which comprising lithium salt. The medium supplemented with lithium salt is used for efficiently inducing pluripotent stem cells. Lithium salt is able to increase the production efficiency of mouse iPS cells by 5-60 times. The present method for inducing iPS cells is in favor of improving the safety of iPS technique and application of iPS cells in regenerative medicine.Type: ApplicationFiled: November 7, 2011Publication date: November 7, 2013Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Xin Xie, Quan Wang
-
Patent number: 8574865Abstract: Methods and assays for identifying a compound that modulates a protein-protein interaction between a first and a second protein. The methods and assays require a protease that is attached to the second protein and a split and rearranged reporter activating protein that is attached to the first protein, wherein the reporter activating protein comprises a cleavage site for the protease that is interposed between two portions of the reporter activating protein and wherein the two portions of the reporter activating protein are in a rearranged order.Type: GrantFiled: August 28, 2008Date of Patent: November 5, 2013Assignee: SanofiInventors: Paul Steven Wright, Paul Weissensee, Haifeng Eishingdrelo, Jidong Cai
-
Publication number: 20130288233Abstract: The invention relates to a method of detecting and quantifying small peptides derived from proteins from a range of different clinical samples using the Selective Reaction Monitoring (SRM) profiling technique. By targeting these unique peptides which specifically identify particular proteins, the present invention enables multiple samples to be run in a multiplexed fashion in order to identify, diagnose, quantitate and profile a full range of benign and pathologic entities, including but not limited to, the complete range of cancers and the spectrum of inflammatory diseases, including inflammatory cell typing and bone marrow cell typing. The SRM assay is capable of performing clinical blood typing and it can also act as a diagnostic test to identify women at highest risk for cervical cancer base on Human Papillomavirus (HPV) testing.Type: ApplicationFiled: September 21, 2011Publication date: October 31, 2013Applicant: MAP DIAGNOSTICS PTY LTD.Inventor: Rachael Murray
-
Publication number: 20130289142Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 1, 2013Publication date: October 31, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20130288230Abstract: The invention presents a method of identifying natural biopolymer—a protein, DNA, RNA in biological fluids and environmental objects, which is based only on the structure of the biopolymer and does not require pathogen genome sequencing, or animals vaccination by biopolymer-antigen. For this purpose the biopolymer itself is taken—a protein, DNA, or RNA, that is fragmented with enzyme to oligomer fragments—a mixture of oligopeptides, oligonucleotides DNA mixture, mixture of RNA oligonucleotides, without dividing the mixture into individual components, then carboxylation of structure in oligomer components is performed by acylation or alkylation.Type: ApplicationFiled: March 25, 2013Publication date: October 31, 2013Inventors: Artur Martynov, Boris S. Farber, Sonya Sophya Farber
-
Patent number: 8569007Abstract: The present invention includes a method for reducing the appearance of false positive bands in SDS-PAGE analysis of proteolytic digestion, of a sample that comprises an immunoglobulin polypeptide, at pH 8.8.Type: GrantFiled: January 4, 2012Date of Patent: October 29, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Kimberly Margaret Louise May, Susan V. Cannon-Carlson, Brittany Charlotte Larkin, Collette Marie Cutler
-
Patent number: 8568716Abstract: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.Type: GrantFiled: June 16, 2006Date of Patent: October 29, 2013Assignee: Proteon Therapeutics, Inc.Inventor: F. Nicholas Franano
-
Patent number: 8569071Abstract: The present teachings provide methods for analyzing one or more amine-containing compounds in one or more samples using isobaric labels and parent-daughter ion transition monitoring (PDITM). In various embodiments, the methods comprise the steps of: (a) labeling one or more amine-containing compounds with different isobaric tags from a set of isobaric tags, each isobaric tag comprising a reporter ion portion; (b) combining at least a portion of each of the isobarically labeled amine-containing compounds to produce a combined sample; (c) subjecting at least a portion of the combined sample to PDITM; (d) measuring the ion signal of one or more of the transmitted reporter ions; and (e) determining the concentration of one or more of the isobarically labeled amine-containing compounds based at least on a comparison of the measured ion signal of the corresponding reporter ion to one or more measured ion signals of a standard compound.Type: GrantFiled: September 8, 2009Date of Patent: October 29, 2013Assignee: DH Technologies Development Pte. Ltd.Inventors: Subodh B. Nimkar, Subhasish Purkayastha, Darryl Pappin, Scott Daniels
-
Publication number: 20130281320Abstract: The present invention provides methods of screening an agent for an activity in an isolated organ, e.g., eye, from a teleost, e.g., zebrafish. Methods of isolating eyes from zebrafish are provided. Methods of screening an agent for an ocular activity in the isolated eye are provided. Methods of screening an agent for an ocular activity in a model of ocular disease or disorder are provided. Methods of screening an agent for an ocular activity in the isolated eye and for screening the agent for cell death and/or toxic activity in the eye or other organ or tissue are provided. The invention further provides high throughput methods of screening agents for an activity in isolated eyes of zebrafish in multi-well plates.Type: ApplicationFiled: January 4, 2013Publication date: October 24, 2013Inventors: Patricia McGrath, Wen Lin Seng
-
Publication number: 20130280728Abstract: The present invention relates to a method for processing a wax-embedded biological sample, the use of poly(organosiloxane)s for liquefying the embedding medium of a wax-embedded biological sample and a kit for processing a wax-embedded biological sample.Type: ApplicationFiled: December 23, 2011Publication date: October 24, 2013Applicant: QIAGEN GMBHInventor: Martin Schlumpberger
-
Publication number: 20130280744Abstract: It is an object of this invention to provide an environmental biological allergen measurement method capable of simple and low-cost measurement of the amount of an environmental biological allergen without using anti-allergen antibodies or a special substrate, and to provide a simple biological allergen quantification kit for carrying out the method. The object can be achieved by a biological allergen measurement method characterized in that the amount of an environmental biological allergen is measured by bringing a test substance into contact with a water-soluble gel or aqueous solution containing a substrate of the protease of the environmental biological allergen, and by quantifying the physical change of the water-soluble gel or the aqueous solution caused by the effect of the protease contained in the test substance on the substrate.Type: ApplicationFiled: October 31, 2011Publication date: October 24, 2013Applicant: SUNSTAR ENGINEERING INC.Inventors: Miwa Ishii, Masumi Ideguchi, Toru Oka
-
Publication number: 20130280742Abstract: Embodiments of the invention include methods of determining the allergen content of a composition. Embodiments of the invention may include providing a composition comprising an allergen; at least partially purifying the allergen from the composition to form an extract; and determining the amount of allergen in the extract using liquid chromatography with ultraviolet and mass spectrometric detection.Type: ApplicationFiled: August 22, 2011Publication date: October 24, 2013Applicant: DOW AGROSCIENCES LLCInventors: Scott A. Young, Barry W. Schafer, Krishna Kuppannan, Samir Julka, Dave R. Albers
-
Publication number: 20130280743Abstract: A method of differentiating among the presence of ductal carcinoma in situ in the breast, benign fibroadenoma of the breast, and non-cancerous breast tissue in a subject is disclosed. The method comprises: measuring the concentration of at least one protein biomarker selected from a group of forty-nine differentially expressed proteins in the saliva of persons with DCIS, or benign fibroadenoma, or in persons who are cancer-free. The resulting test data is compared to a reference panel. From the comparison the presence in the subject of either ductal carcinoma in situ of the breast, or benign fibroadenoma of the breast is determined.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Charles F. STRECKFUS, William P. DUBINSKY, Lenora R. BIGLER
-
Publication number: 20130280255Abstract: This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).Type: ApplicationFiled: July 8, 2013Publication date: October 24, 2013Inventors: Xuanyong Lu, Timothy M. Block
-
Patent number: 8562983Abstract: The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.Type: GrantFiled: August 22, 2008Date of Patent: October 22, 2013Assignee: Proteon Therapeutics, Inc.Inventor: F. Nicholas Franano
-
Publication number: 20130273586Abstract: The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Gerard M. TURINO, Shuren Ma, Yong Y. Lin, Seymour Leiberman
-
Publication number: 20130273028Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: January 4, 2012Publication date: October 17, 2013Applicant: ThromboGenics NVInventor: Richard Reinier Zwaal
-
Patent number: 8557536Abstract: An object of the present invention is to provide a detection method capable of detecting articular cartilage degeneration or damage in which the abnormality cannot be detected in a radiograph in a simple method and with high accuracy, a method of evaluating the rate of progression of articular cartilage degeneration or damage, and the like. The present invention as a means for achieving the object provides a method of detecting articular cartilage degeneration or damage which cannot be detected in a radiograph, by using the concentration of keratan sulfate in a sample derived from blood as an index, and the like. Further, the present invention provides a method of evaluating the rate of progression of articular cartilage degeneration or damage by using the concentration of keratan sulfate in a sample derived from blood as an index, and the like.Type: GrantFiled: February 5, 2008Date of Patent: October 15, 2013Assignee: Seikagaku CorporationInventors: Shigeyuki Wakitani, Masashi Nawata, Kyosuke Miyazaki, Hiroyuki Masuda, Hiroshi Fujita, Yasuhiro Kurahashi
-
Publication number: 20130267430Abstract: Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody.Type: ApplicationFiled: June 14, 2012Publication date: October 10, 2013Applicant: SAPPORO MEDICAL UNIVERSITYInventors: Tsukasa HORI, Yasuo KOKAI, Yasuyoshi NAISHIRO, Hiroyuki TSUTSUMI, Kohzoh IMAI
-
Publication number: 20130266978Abstract: A method for estimating molecular parameters in a sample comprising the following steps: passing the sample through a processing chain including a chromatography step; thereby obtaining a representative signal of molecular parameters as a function of at least one variable of the processing chain; and estimating the molecular parameters using a signal processing device by inverting a direct analytical model of said signal defined as a function of the molecular parameters and technical parameters of the processing chain. Moreover, the processing chain includes a step for multiple measurements of the same product from the chromatography step, the direct analytical model of said signal comprises modelling of this multiple measurement step, and this modelling requires at least one common characteristic of the signals obtained from these multiple measurements.Type: ApplicationFiled: April 5, 2013Publication date: October 10, 2013Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventor: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT
-
Patent number: 8551727Abstract: Disclosed are a metal nanoparticle onto which a peptide substrate specifically degraded by protease and fluorophore are chemically modified for selectively imaging protease expressed in cell and in tissue in a human body, and the use thereof. Also, a quantitative analysis method of protease using the metal nanoparticle, a cell imaging method and a drug screening method of inhibiting a protease overexpression are provided. In detail, the present invention is directed to a metal nanoparticle having a peptide substrate and fluorophore coupled thereto, the peptide substrate and the fluorophore being specifically degraded by due to a protease activated in various ways in cell and in a human body to exhibit fluorescence. Hence, the metal nanoparticle can be used to rapidly screen activation and inhibition of the protease in the imaging manner.Type: GrantFiled: April 10, 2008Date of Patent: October 8, 2013Assignee: Korea Institute of Science and TechnologyInventors: Ick-Chan Kwon, Kui-Won Choi, Kwang-Meyung Kim, Cheol-Hee Ahn, In-Chan Youn, Seul-Ki Lee, Kyeong-Soon Park
-
Publication number: 20130260406Abstract: The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: John Matthew Koomen, Elizabeth Renee Remily, Kaaron Benson, Mohamad Hussein
-
Publication number: 20130261045Abstract: The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with ?-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits ?-secretase activity. The subject invention also provides methods to increase ?-secretase expression and/or activity in cells by administering polyphenol flavonoids like (?)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of A?1-40 or A?1-42 by administering the EGCG and EC compounds, their analogs, metabolites, and prodrugs.Type: ApplicationFiled: December 7, 2012Publication date: October 3, 2013Inventors: ROLAND DOUGLAS SHYTLE, JUN TAN
-
Publication number: 20130260405Abstract: In order to provide a fluorescence measurement method and a fluorescence measurement device that are provided by a simpler structure, and are more inexpensive and capable of measuring an amount of fluorescence using a very small amount of sample, using a fluorescence measurement device including a light-blocking measurement box to which a microtube is loaded; a container support part disposed inside the measurement box, the container support part vertically supporting the microtube; an excitation light source part disposed inside the measurement box, the excitation light source part including a light source that horizontally irradiates excitation light a sidewall surface of the loaded microtube; and a fluorescence detection part provided at an upper portion of the measurement box and above the loaded microtube, the fluorescence detection part measuring an amount of fluorescence in a particular wavelength range from a target sample, a microtube charged with a target liquid sample is loaded into the measurementType: ApplicationFiled: September 28, 2011Publication date: October 3, 2013Applicants: THE YOSHIDA DENTAL MFG. CO., LTD., PEPTIDE SUPPORT LTD.Inventors: Norikazu Nishino, Mitsuhiro Fukamachi, Fumio Obayashi
-
Publication number: 20130260404Abstract: Latent fluorescent tags, including compounds of Formula I, methods of making latent fluorescent tags, and methods of fluorescently labeling living cells are provided. The compounds of Formula I have the structure: wherein each of the variables are as defined herein.Type: ApplicationFiled: April 3, 2012Publication date: October 3, 2013Inventors: Angele Sjong, Kraig Anderson
-
Publication number: 20130259847Abstract: Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g.Type: ApplicationFiled: September 7, 2012Publication date: October 3, 2013Applicant: BERG PHARMA LLCInventors: Vivek K. Vishnudas, Rangaprasad Sarangarajan, Niven Rajin Narain, Min Du, Tony Walshe
-
Publication number: 20130261015Abstract: A method for diagnosing cancer using information on aberrant glycosylation of glycoproteins, which is related with cancer progression. More particularly, the present invention relates to a peptide marker for cancer diagnosis and a method for diagnosing cancer using the peptide marker, wherein glycoproteins aberrantly glycosylated due to cancer incidence and progression is isolated using lectin; and marker peptides generated by hydrolysis or the glycoproteins isolated by the lectin is selected and quantified.Type: ApplicationFiled: March 26, 2013Publication date: October 3, 2013Applicant: Korea Basic Science InstituteInventors: Yeong Hee AHN, Jong Shin YOO, Park Min SHIN
-
Publication number: 20130252906Abstract: Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. Also provided is an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.Type: ApplicationFiled: October 14, 2011Publication date: September 26, 2013Applicant: AMICUS THERAPEUTICS, INC.Inventors: Eric Richard Sjoberg, Gary Lee
-
Publication number: 20130253005Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.Type: ApplicationFiled: April 29, 2011Publication date: September 26, 2013Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
-
LIQUID TISSUE PREPARATION FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICALLY SAMPLES, TISSUES AND CELLS
Publication number: 20130252840Abstract: The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multi-use biomolecule lysate. This method allows for simultaneous extraction, isolation, solublization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: Expression Pathology, Inc.Inventors: Marlene M. Darfler, David B. Krizman -
Patent number: 8541192Abstract: The invention provides methods used to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be identified by contacting isolated USP1 with a test compound in the presence of monoubiquitinated proliferating cell nuclear antigen (PCNA), monoubiquitinated human Fanconi anemia group D2 (FANCD2), or ubiquitin-7-amido-4-methylcoumarin, and detecting the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin using an antibody or fluorescence, wherein a decrease in the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin in the presence of the test compound relative to the absence of the test compound identifies said test compound as an inhibitor of USP1 deubiquitinase.Type: GrantFiled: July 13, 2010Date of Patent: September 24, 2013Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Alan D. D'Andrea
-
Patent number: 8541193Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with a cationic anti-microbial peptide that is degradable by an enzyme produced and/or secreted by a microorganism, and detecting degradation or the absence of degradation of the peptide, as an indicator of the presence or absence of the enzyme in the sample, and thus indicative of the presence or absence of a microorganism in the sample. The present invention also features a biosensor for detecting the presence or absence of a microorganism in a sample.Type: GrantFiled: December 22, 2011Date of Patent: September 24, 2013Assignee: Systagenix Wound Management (US), Inc.Inventors: Mitchell T. Sanders, Gerard Colpas, Shite Sebastian, Diane Ellis-Busby
-
Publication number: 20130244264Abstract: A method for measuring an analyte is described that includes the steps of: i) preparing a reagent (D) in which an enzyme (A) and an enzyme (B) coexist in the absence of the analyte; ii) bringing the analyte into contact with the enzyme (A) and the enzyme (B) so that the enzyme (A) acts on the analyte to produce a product (E), on which the enzyme (B) does not substantially act, from the analyte; iii) producing a product (C) by allowing the enzyme (A) or an enzyme (F) that is different from the enzyme (A) that acts on the analyte to produce a product (C) to act on the analyte and/or the product (E); and iv) detecting the product (C) by the enzyme (B).Type: ApplicationFiled: March 11, 2013Publication date: September 19, 2013Applicants: KIKKOMAN BIOCHEMIFA COMPANY, ARKRAY, INC.Inventors: Koji Sugiyama, Satoshi Yonehara, Kazuhiko Shimoji